Contact a Rep

CONTACT A REP

Interested in connecting with an ANI Pharmaceuticals representative?

Fill out the request form below if you wish to be contacted with more information on Cortrophin Gel.

This form is for healthcare professionals only. If you are a patient looking to contact customer service, please call 1-800-434-1121 or email info@anipharmaceuticals.com.

* = Required

I confirm and agree to the following:*

I am a licensed US healthcare professional. I understand that this information may be used by ANI Pharmaceuticals and its affiliates and partners or third parties working on behalf of ANI Pharmaceuticals to contact me. I agree that the personal information I provide may be used by ANI Pharmaceuticals, or other companies acting on its behalf, to contact me via mail, email, or otherwise provide me with information about educational materials, market research, products, and services concerning Cortrophin Gel. I give my permission for ANI Pharmaceuticals to use my information for reasonable business purposes as permitted or required by law. Neither ANI Pharmaceuticals nor the companies working on its behalf may sell or rent my personal information except for as set forth in the ANI Pharmaceuticals Privacy Policy.

* = Required

Consider cortrophin gel as the next step for your appropriate patients

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly. It is indicated for:

Short-term administration as an adjunctive therapy during an acute episode or exacerbation in rheumatoid arthritis, including juvenile rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; and acute gouty arthritis.
Exacerbations or as maintenance therapy in select cases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis).

Rheumatoid Arthritis Flares

Acute Gouty Arthritis Flares

Meet Ian, a crossing guard living with acute gouty arthritis flares

68 years old, diagnosed with acute gouty arthritis 7 years ago
Flares were previously treated with corticosteroids, NSAIDs, and colchicine, but may require an additional treatment option
Also on background therapy for treatment of uric acid levels
Ian needs an additional treatment option for his acute gouty arthritis flares

Are you seeing patients like Ian in your practice? If so, consider Cortrophin Gel—the only FDA-approved ACTH therapy for appropriate patients with acute gouty arthritis flares.^1,2

Are you seeing patients like Ian in your practice? If so, consider Cortrophin Gel—the only FDA-approved ACTH therapy for appropriate patients with acute gouty arthritis flares.^1,2

Hypothetical Patient

Hypothetical Patient

Learn more about Cortrophin Gel, including the dosage for acute gouty arthritis flares

The prevalence of acute gouty arthritis flares

The American College of Rheumatology defines frequent gout flares as ≥2 per year.³

One study (N=2778) showed that 24.6% of patients with gout experienced 2 or more flares in a 12-month period.⁴

24.6%

Of these patients with 2 or more flares, 51% were being treated with a uric acid-lowering therapy (allopurinol).⁴

51%

ACTH=adrenocorticotropic hormone; NSAIDs=nonsteroidal anti-inflammatory drugs.

Select Cases of Systemic Lupus Erythematosus

Select Cases of Dermatomyositis (Polymyositis)

Proposed Mechanism
of Action

Discover how ACTH may work by viewing its proposed mechanism of action (MOA).

Prescribing
Cortrophin Gel

Access important
enrollment information.

Prescribe & Enroll

Provider & Patient
Resources

Explore downloadable resources, as well as educational materials for your appropriate patients, including injection guides.

References: 1. Cortrophin Gel. Prescribing Information. 2. Acthar Gel. Prescribing information; February 2024. 3. FitzGerald JD, et al. Arthritis Care Res. 2020;72(6):744-760. 4. Proudman C, et al. Arthritis Res Ther. 2019;21:132.

Indications

Important Safety Information

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly. It is indicated for:

Cortrophin Gel is indicated for:

Acute exacerbations of multiple sclerosis.
Short-term administration as an adjunctive therapy during an acute episode or exacerbation in rheumatoid arthritis, including juvenile rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; and acute gouty arthritis.
Exacerbations or as maintenance therapy in select cases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis).
Severe erythema multiforme (Stevens-Johnson syndrome) and severe psoriasis.
Atopic dermatitis and serum sickness.
Severe acute and chronic allergic and inflammatory conditions affecting the eye and its adnexa, such as allergic conjunctivitis, keratitis, iritis and iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, and anterior segment inflammation.
Symptomatic sarcoidosis.
Inducing a diuresis or remission of proteinuria due to nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.

Contraindications

Cortrophin Gel is contraindicated for intravenous administration.
Cortrophin Gel is contraindicated in patients who have any of the following conditions: scleroderma; osteoporosis; systemic fungal infections; ocular herpes simplex; recent surgery; history of or the presence of a peptic ulcer; congestive heart failure; hypertension; primary adrenocortical insufficiency; adrenocortical hyperfunction; or sensitivity to proteins derived from porcine sources.

Warnings and Precautions

Infections: Corticotropin therapy may increase susceptibility to infections and may mask the symptoms of infections.
Adrenal insufficiency: Prolonged corticotropin therapy can increase the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by gradually reducing the corticotropin dosage. Hormone therapy should be reinstituted if stressful situations arise during discontinuation.
Elevated blood pressure, salt and water retention, and hypokalemia: Corticotropin can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium or calcium.
Masking symptoms of other diseases: Corticotropin may only suppress signs and symptoms of chronic disease without altering the natural course of disease.
Psychiatric reactions: Psychic derangements may appear when corticotropin is used, ranging from euphoria, insomnia, mood swings, personality changes, and depression to psychosis. Existing conditions may be aggravated.
Ophthalmic reactions: Prolonged use of corticotropin may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves.
Immunogenicity potential: Prolonged administration of Cortrophin Gel may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Cortrophin Gel activity.
Vaccination: Patients should not be vaccinated against smallpox while on corticotropin therapy. Other immunizations should be undertaken with caution due to possible neurologic complications and lack of antibody response.
Use in patients with hypothyroidism and cirrhosis: There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis.
Use in patients with latent tuberculosis or tuberculin reactivity: Closely observe for reactivation of the disease.
Comorbid diseases: Corticotropin should be used with caution in patients with diabetes, abscess, pyogenic infections, diverticulitis, renal insufficiency, and myasthenia gravis.
Growth and development: Carefully observe growth and development of infants and children on prolonged corticotropin therapy.
Acute gouty arthritis: Treatment of acute gouty arthritis should be limited to a few days. Conventional concomitant therapy should be administered during corticotropin treatment and for several days after it is stopped.
Drug interactions: Aspirin should be used cautiously with corticotropin in hypoprothrombinemia.
Pregnancy: Since fetal abnormalities have been observed in animals, Cortrophin Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Adverse Reactions

Adverse reactions for Cortrophin Gel include fluid or sodium retention; muscle weakness; osteoporosis; peptic ulcer with possible perforation and hemorrhage; injection site reactions; impaired wound healing; hypertension; convulsions; headache; development of Cushingoid state; suppression of growth in children; anaphylaxis (anaphylactic shock, urticaria, respiratory compromise, edema); and weight gain. These are not all the adverse reactions reported with Cortrophin Gel.

Please see full Prescribing Information.

Indications

Cortrophin Gel is a prescription medicine that is injected subcutaneously or intramuscularly. It is indicated for:

Cortrophin Gel is indicated for:

Acute exacerbations of multiple sclerosis.
Short-term administration as an adjunctive therapy during an acute episode or exacerbation in rheumatoid arthritis, including juvenile rheumatoid arthritis; psoriatic arthritis; ankylosing spondylitis; and acute gouty arthritis.
Exacerbations or as maintenance therapy in select cases of systemic lupus erythematosus and systemic dermatomyositis (polymyositis).
Severe erythema multiforme (Stevens-Johnson syndrome) and severe psoriasis.
Atopic dermatitis and serum sickness.
Severe acute and chronic allergic and inflammatory conditions affecting the eye and its adnexa, such as allergic conjunctivitis, keratitis, iritis and iridocyclitis, diffuse posterior uveitis and choroiditis, optic neuritis, chorioretinitis, and anterior segment inflammation.
Symptomatic sarcoidosis.
Inducing a diuresis or remission of proteinuria due to nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus.

Important Safety InformationContraindications

Cortrophin Gel is contraindicated for intravenous administration.
Cortrophin Gel is contraindicated in patients who have any of the following conditions: scleroderma; osteoporosis; systemic fungal infections; ocular herpes simplex; recent surgery; history of or the presence of a peptic ulcer; congestive heart failure; hypertension; primary adrenocortical insufficiency; adrenocortical hyperfunction; or sensitivity to proteins derived from porcine sources.

Warnings and Precautions

Infections: Corticotropin therapy may increase susceptibility to infections and may mask the symptoms of infections.
Adrenal insufficiency: Prolonged corticotropin therapy can increase the potential for adrenal insufficiency after withdrawal of the medication. Adrenal insufficiency may be minimized by gradually reducing the corticotropin dosage. Hormone therapy should be reinstituted if stressful situations arise during discontinuation.
Elevated blood pressure, salt and water retention, and hypokalemia: Corticotropin can cause elevation of blood pressure, salt and water retention, and increased excretion of potassium or calcium.
Masking symptoms of other diseases: Corticotropin may only suppress signs and symptoms of chronic disease without altering the natural course of disease.
Psychiatric reactions: Psychic derangements may appear when corticotropin is used, ranging from euphoria, insomnia, mood swings, personality changes, and depression to psychosis. Existing conditions may be aggravated.
Ophthalmic reactions: Prolonged use of corticotropin may produce posterior subcapsular cataracts and glaucoma with possible damage to the optic nerves.
Immunogenicity potential: Prolonged administration of Cortrophin Gel may increase the risk of hypersensitivity reactions. Cases of anaphylaxis have been reported in the postmarketing setting. Neutralizing antibodies with chronic administration may lead to loss of endogenous ACTH and Cortrophin Gel activity.
Vaccination: Patients should not be vaccinated against smallpox while on corticotropin therapy. Other immunizations should be undertaken with caution due to possible neurologic complications and lack of antibody response.
Use in patients with hypothyroidism and cirrhosis: There is an enhanced effect in patients with hypothyroidism and in those with cirrhosis.
Use in patients with latent tuberculosis or tuberculin reactivity: Closely observe for reactivation of the disease.
Comorbid diseases: Corticotropin should be used with caution in patients with diabetes, abscess, pyogenic infections, diverticulitis, renal insufficiency, and myasthenia gravis.
Growth and development: Carefully observe growth and development of infants and children on prolonged corticotropin therapy.
Acute gouty arthritis: Treatment of acute gouty arthritis should be limited to a few days. Conventional concomitant therapy should be administered during corticotropin treatment and for several days after it is stopped.
Drug interactions: Aspirin should be used cautiously with corticotropin in hypoprothrombinemia.
Pregnancy: Since fetal abnormalities have been observed in animals, Cortrophin Gel should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Adverse Reactions

Adverse reactions for Cortrophin Gel include fluid or sodium retention; muscle weakness; osteoporosis; peptic ulcer with possible perforation and hemorrhage; injection site reactions; impaired wound healing; hypertension; convulsions; headache; development of Cushingoid state; suppression of growth in children; anaphylaxis (anaphylactic shock, urticaria, respiratory compromise, edema); and weight gain. These are not all the adverse reactions reported with Cortrophin Gel.

Please see full Prescribing Information.